Introduction {#s1}
============

Myocarditis is pathologically and clinically defined as an inflammatory disease of the heart muscle based on histological, immunological, and immunohistochemical criteria of cardiomyopathy classification from the World Health Organization (WHO) ([@B26]). Myocarditis often arises from infection with common viruses, such as respiratory viruses and enteroviruses, and is most commonly associated with coxsackievirus B ([@B6]). Myocarditis infection can be subdivided into three pathological stages ([@B22]). In the first stage, viral-mediated lysis directly destroys cardiomyocytes, leading to cardiomyocyte damage and cardiac dilation ([@B23]). The second stage is imbalance of immune regulation resulting from myocardial cell damage ([@B16]). Finally, the typical manifestation of dilated cardiomyopathy (DCM) occurs due to extensive myocardial injury ([@B3]). Viral myocarditis (VM) has the characteristics of myocardial inflammation, often developing into chronic dilated cardiomyopathy, acute myocarditis and even congestive heart failure ([@B13]). VM accounts for 12% of sudden deaths in patients under 40 years of age and is the leading cause of dilated cardiomyopathy, resulting in 50% of patients deaths within 1--2 years after diagnosis ([@B5]). The incidence of myocarditis worldwide was reported a 22 cases per 100,000 individuals in 2013, and about 1.5 million patients were diagnosed with myocarditis according to the ninth revised diagnosis of the International Classification of Diseases ([@B7]). For VM, antiviral drugs, physical activity restriction and myocardial nutrition are the main routine clinical treatments. Patients should follow the current guidelines for heart failure treatment in cases of left ventricular dysfunction or symptomatic heart failure ([@B27]). However, establishing the potential benefits of immunomodulators and antiviral therapy is currently at the preliminary research stage ([@B26]).

AS-IV, the essential active component of astragalus, has been traditionally used to treat various diseases. This compound is frequently reported to exert protective effects on cardiovascular, nervous and immune systems due to its antioxidant and activitiesanti-apoptotic activities as well as regulatory effects on calcium balance ([@B28]). Systematic studies on animal models play an important role in drug research and provide substantial evidence to support application in the clinic ([@B29]). The purposes of the present study was to investigate the efficacy and potential mechanisms of action of AS-IV in animal models of VM.

Methods {#s2}
=======

The study was carried out according to the Preferred Reporting Items for Systematic Review and MetaAnalyses ([@B30]).

Search Strategies {#s2_1}
-----------------

Based on the literature retrieval from PubMed, Wanfang database, EMBASE, China National Knowledge Infrastructure (CNKI), Cochrane Library and VIP databases, animal experimental studies of AS-IV for VM were identified. All search strategies were performed from inception until October 2018. We selected the following terms: 1. Astragaloside; 2. Myocarditis; 3. 1 AND 2; 4. Animals NOT humans; 5. 3 AND 4.

Eligibility Criteria {#s2_2}
--------------------

Studies that met the following criteria were included: (1) animal models of VM were established through various ways, (2) treatment groups were administered any dose of AS-IV only, and comparators given non-functional and isasteric liquid (carboxymethyl cellulose or normal saline) or no treatment, and (3) the primary outcome measures were mortality rate, histopathological changes of myocardium, indicators of cardiac ultrasound, cardiac troponin, cardiac enzymes and/or level of ST-segment depression. Cardioprotective mechanisms of AS-IV action against VM were used as the secondary outcome measure. Exclusion criteria were as follows: (1) duplicate publication, (2) not *in vivo* studies, (3) comparison with other traditional Chinese medicine (TCM), (4) combinations with other medicine, and (5) lack of a control group.

Data Extraction {#s2_3}
---------------

Two authors independently extracted the following details: (1) name of the first author and publication year, (2) characteristics (species, number, sex, and weight) of the animals used in each study, (3) methods to establish animal models of VM, (4) the therapeutic regimens of treatment and control groups, including method of administration, therapeutic drug dosage and sessions of treatment, (5) primary and secondary outcomes. If the results were obtained at different time-points or following administration of different doses of drug, only the final measured value and data obtained with the highest dose of drug were included. We attempted to contact authors for more information when published data for some records were only shown in a graphical format. In cases where no response was received, data in the graph were measured.

Risk of Bias in Individual Studies {#s2_4}
----------------------------------

The risk of bias was assessed by two independent authors through applying the ten-item scale ([@B12]), with minor modifications. Risk of bias of the following domains were assessed: A: sequence generation; B: baseline characteristics; C: allocation concealment; D: random housing and other animal welfare; E: blinding of caregivers and/or investigators; F: random outcome assessment; G: blinding of outcome assessor; H: complete outcome data; I: selective outcome reporting; J: other sources of bias. One point was awarded for each item. Divergent findings between the two authors were settled through resolving by consensus or arbitration by the corresponding author.

Statistical Analysis {#s2_5}
--------------------

RevMan version 5.3 was utilized for statistical analysis. Standardized mean difference (SMD) instead of Mean differences (MDs) was employed as a summary statistic when data were not reported on the same scale. Heterogeneity and choice of effects models were investigated with the aid of standard chi-square test and I² statistic test. Differences were considered significant at P values \<0.05.

Results {#s3}
=======

Study Selection {#s3_1}
---------------

We identified a total of 540 hints on the basis of pertinent literature retrieval from the databases. After removing 439 reduplicated or irrelevant articles, 101 reports remained. Next, we excluded 53 non-animal studies through screening the titles and abstracts. Overall, 33 articles were excluded after reading the remaining full-text articles owing to: (1) no predetermined outcome index, (2) comparison with other TCM, (3) combination with other medicine, (4) non-viral myocarditis models, and (5) lack of a control group, leading to the final selection of 15 eligible articles ([@B37]; [@B36]; [@B38]; [@B33]; [@B19]; [@B17]; [@B20]; [@B4]; [@B10]; [@B34]; [@B39]; [@B18]; [@B8]; [@B31]; [@B35]) ([**Figure 1**](#f1){ref-type="fig"}).

![Summary of the process for identifying candidate studies.](fphar-10-01388-g001){#f1}

Characteristics of Included Studies {#s3_2}
-----------------------------------

Twelve studies were published in Chinese ([@B37]; [@B36]; [@B33]; [@B19]; [@B17]; [@B20]; [@B10]; [@B34]; [@B39]; [@B18]; [@B31]; [@B35]) and three studies in English ([@B38]; [@B4]; [@B8]) between 2006 and 2015. Fourteen studies used male BALB/C mice ([@B37]; [@B36]; [@B38]; [@B33]; [@B19]; [@B17]; [@B20]; [@B4]; [@B10]; [@B34]; [@B39]; [@B18]; [@B8]; [@B31]) and one used male Kunming mice ([@B35]). Eight studies used mice weighing 12--16 g for experiments ([@B37]; [@B36]; [@B19]; [@B17]; [@B20]; [@B10]; [@B18]; [@B31]), one used mice weighing 12--14 g ([@B33]), three used mice weighing 14--16 g ([@B38]; [@B34]; [@B39]), one used mice weighing 18--22 g ([@B35]) and two did not provide information on mouse weight ([@B4]; [@B8]). VM models were established by intraperitoneal injection of CVB3 in all studies. In terms of AS-IV dosage, one study utilized 4.36 g/kg/d ([@B35]), three utilized 600 mg/kg/d ([@B19]; [@B34]; [@B31]), one utilized 300 mg/kg/d ([@B4]), one utilized 120 mg/kg/d ([@B38]), one utilized 40 mg/kg/d ([@B8]), one utilized 1 mg/kg/d ([@B33]), two utilized 0.6 mg/kg/d ([@B20]; [@B10]), and five did not specify the dose used ([@B37]; [@B36]; [@B17]; [@B39]; [@B18]). Twelve studies utilized mortality rate as outcome measure ([@B37]; [@B36]; [@B38]; [@B33]; [@B19]; [@B17]; [@B4]; [@B10]; [@B34]; [@B18]; [@B8]; [@B31]) and histopathological changes of myocardium were assessed in nine studies ([@B36]; [@B33]; [@B19]; [@B17]; [@B34]; [@B39]; [@B18]; [@B8]; [@B31]). Left ventricular ejection fraction (LVEF) was reported in one study ([@B4]), shortening fraction (FS) in two studies ([@B4]; [@B8]) and left ventricular endsystolic dimensions (LVEDd) in two studies ([@B4]; [@B8]), but the level of ST-segment depression was not mentioned. The cardiac troponin I (cTnI) level was reported in one study ([@B8]), creatine kinase (CK) in one study ([@B8]), superoxide dismutase (SOD) in two studies ([@B33]; [@B19]), glutathione (GSH) in two studies ([@B33]; [@B19]), reative oxygen species (ROS) in one study ([@B33]), tumor necrosis factor-α (TNF-α) in two studies ([@B39]; [@B8]), myocardial apoptosis index in two studies ([@B37]; [@B20]), B-cell lymphoma-2 (Bcl-2) in two study ([@B20]), Bcl2-associated X (Bax) in one study ([@B20]), and nuclear factor κB (NF-κB) in one study ([@B8]). The characteristics of the included studies are summarized in [**Table 1**](#T1){ref-type="table"}.

###### 

Characteristics of the 15 included studies.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study (years)   Species (Sex; n = experimental/control group)   Weight   Model (method)                                                                                                                           Treatment group (Method to astragal sides)                                                                 Control group                                                                                                                             Outcome Index (time)                                             Intergroup Differences
  --------------- ----------------------------------------------- -------- ---------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- ------------------------
  [@B37]          BALB/C mice (male; 18/18)                       12-16g   By intraperitoneal injection of EMEM solution containing 1×10\^^9^ TCID50 CVB3 (0.1ml) at the age of 4 weeks                             By intragastric administration of 9% AS-IV (0.1ml; qd) for 7d after establishing model                     By intragastric administration of normal saline (0.1ml; qd) for 7d after establishing model                                               1.Mortality rate\                                                1.P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2.CVF\                                                           2.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         3.PIP\                                                           3.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         4. PIIINP\                                                       4.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         5.Myocardial apoptosis index                                     5. P \< 0.01

  [@B36]          BALB/C mice (male; 20/20)                       12-16g   By intraperitoneal injection of CVB3 at the age of 4 weeks                                                                               By intragastric administration of 9% AS-IV (0.1ml; qd) for 7d after establishing model                     By intragastric administration of sodium carboxymethyl cellulose solution (0.1ml; qd) for 7d after establishing model                     1.Mortality rate\                                                1.P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2.Histopathological changes of myocardium                        2.P \< 0.01

  [@B38]          BALB/C Mice (male; 15/16)                       14-16g   By intraperitoneal injection of CVB3 at the age of 4 weeks                                                                               By intragastric administration of AS-IV (120mg/kg; qd) for 7d after establishing model                     By intragastric administration of isometric normal saline solution (qd) for 7d after establishing model                                   1.Mortality rate\                                                1.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2.HW/BW ratios\                                                  2.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         3.Virus titers of hearts 4.Scores of necrosis and infiltration   3.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          4.P \< 0.01

  [@B33]          BALB/C Mice (male; 30/30)                       12-14g   By intraperitoneal injection of RPIM-1640 solution containing 1 ×10\^^5^ TCID50 CVB3 at the age of 4 weeks                               By intragastric administration of AS-IV (1mg/kg; qd) for 7d after establishing model                       By intragastric administration of isometric sodium carboxymethyl cellulose solution (qd) for 7d after establishing model                  1.Mortality rate\                                                1.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2.Histopathological changes of myocardium\                       2.P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         3.T-SOD\                                                         3.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         4.GSH-PX\                                                        4.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         5.CAT\                                                           5.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         6.MPO\                                                           6.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         7.ROS                                                            7.P \< 0.01

  [@B19]          BALB/C mice (male; 10/10)                       12-16g   By intraperitoneal injection of EMEM solution containing 1×10\^^2^ TCID50 CVB3 (0.1 ml) at the age of 4 weeks                            By intragastric administration of 9% AS-IV (600mg/kg) (0.1ml; qd) for 7d after establishing model          By intragastric administration of normal saline (0.1ml; qd) for 7d after establishing model                                               1.Mortality rate\                                                1.P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2.Histopathological changes of myocardium\                       2.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         3.T-SOD\                                                         3.P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         4.GSH-PX\                                                        4.P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         5.CAT                                                            5.P \< 0.05

  [@B17]          BALB/C mice (male; 15/15)                       12-16g   By intraperitoneal injection of virus culture medium containing 1 ×10\^^2^ TCID50 CVB3 (0.1ml) at the age of 4 weeks                     By intragastric administration of 9% AS-IV (0.1ml; qd) for 14d after establishing model                    By intragastric administration of sodium carboxymethyl cellulose solution (0.1ml; qd) for 14d after establishing model                    1.Mortality rate\                                                1.P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2.Histopathological changes of myocardium\                       2.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         3.MIF protein                                                    3.P \< 0.01

  [@B20]          BALB/C mice (male; 10/10)                       12-16g   By intraperitoneal injection of EMEM solution containing 1 ×10\^^5^ TCID50 CVB3 (0.1ml) at the age of 4 weeks                            By intragastric administration of 9% AS-IV (0.6mg/kg) (0.1ml; qd) for 7d after establishing model          By intragastric administration of normal saline (0.1ml; qd) for 7d after establishing model                                               1.Myocardial apoptosis index\                                    1.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2.Bcl-2\                                                         2.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         3.Bax                                                            3.P \< 0.01

  [@B4]           BALB/C mice (male; 20/30)                       NM       By intraperitoneal injection of CVB3 (100ul) at the age of 4 weeks and treatments monthly for 9 month to induce dilated cardiomyopathy   By intragastric administration of AS-IV (300mg/L; qd) containing drinking water after establishing model   By intragastric administration of isometric plain drinking water (qd) after establishing model                                            1.Mortality rate\                                                1.P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2.LVEDd\                                                         2.P \< 0.001\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         3.LVEDs\                                                         3.P \< 0.001\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         4.LVEF\                                                          4.P \< 0.001\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         5.FS\                                                            5.P \< 0.001\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         6.PICP\                                                          6.P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         7.PINP\                                                          7.p \> 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         8.PICP/PINP ratio\                                               8.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         9.TGF-β1\                                                        9.P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         10.pSmad2/3\                                                     10.P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         11.Smad4\                                                        11.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         12.Smad7                                                         12.p \> 0.05

  [@B10]          BALB/C mice (male; 15/15)                       12-16g   By intraperitoneal injection of Eagle' s culture media containing 1 ×10\^^2^ TCID50 CVB3 (0.1 ml) at the age of 4 weeks                  By intragastric administration of 9% AS-IV (0.6mg/kg; qd) for 15d after establishing model                 By intragastric administration of isometric hydroxymethyl cellulose sodium solution (qd) for 15d after establishing model                 1.IGF-1 in plasma\                                               1.P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2.IGF-1 Protein in myocardium\                                   2.P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         3.IGF-1R Protein in myocardium\                                  3.P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         4.IGFBP3 Protein in myocardium                                   4.P \< 0.05

  [@B34]          BALB/C mice (male; 30/30)                       14-16g   By intraperitoneal injection of CVB3 (0.1ml) at the age of 4 weeks                                                                       By intragastric administration of AS-IV (0.1ml; qd) for 7d after establishing model                        By intragastric administration of normal saline (0.1ml; qd) for 7d after establishing model                                               1.Histopathological changes of myocardium\                       1.P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2.P38MAPK                                                        2.P \< 0.05

  [@B39]          BALB/C mice (male; 30/30)                       14-16g   By intraperitoneal injection of 1 ×10\^^2^ TCID50 CVB3 (0.1ml) at the age of 4 weeks                                                     By intragastric administration of AS-IV (0.1ml; qd) for 7d after establishing model                        By intragastric administration of normal saline (0.1ml; qd) for 7d after establishing model                                               1.Histopathological changes of myocardium\                       1.P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2.TNF-α                                                          2.P \< 0.05

  [@B18]          BALB/C mice (male; 20/20)                       12-16g   By intraperitoneal injection of virus culture medium containing 1 ×10\^^2^ TCID50 CVB3 (0.1ml) at the age of 4 weeks                     By intragastric administration of 9% AS-IV (0.1ml; qd) for 14d after establishing model                    By intragastric administration of sodium carboxymethyl cellulose solution (0.1ml; qd) for 14d after establishing model                    1.Mortality rate\                                                1.P \> 0.003\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2.Histopathological changes of myocardium\                       2.P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         3.Th17\                                                          3.P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         4.IL-23\                                                         4.P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         5.IL-17                                                          5.P \< 0.05

  [@B8]           BALB/C mice (male; 15/15)                       NM       By intraperitoneal injection of 1 ×10\^^3^ TCID50 CVB3 at the age of 6 weeks                                                             By intragastric injection of AS-IV (40mg/kg; qd) for 7d after establishing model                           By intragastric injection of isometric normal saline (qd) for 7d after establishing model                                                 1.The changes of body weight\                                    1.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2.Mortality rate\                                                2.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         3.CK-MB\                                                         3.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         4.cTnI\                                                          4.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         5.Myocarditis score\                                             5.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         6. PWd\                                                          6.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         7.SWd\                                                           7.p \> 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         8.LVEDd\                                                         8.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         9.LVEDs\                                                         9.p \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         10.EF\                                                           10.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         11.FS\                                                           11.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         12.HR\                                                           12.P \> 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         13.TNF-α in myocardium\                                          13.P \< 0.001\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         14.IL-1β in myocardium\                                          14.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         15.IL-6 in myocardium\                                           15.P \< 0.001\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         16.MCP-1 in myocardium\                                          16.P \< 0.001\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         17.TNF-α in serum\                                               17.P \< 0.001\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         18.IL-1β in serum\                                               18.P \< 0.001\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         19.IL-6 in serum\                                                19.P \< 0.001\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         20.MCP-1 in serum\                                               20.P \< 0.001\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         21.CD3\                                                          21.P \< 0.001\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         22.CD11b\                                                        22.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         23.NF-κB DNA\                                                    23.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         24.A20                                                           24.P \< 0.001

  [@B31]          BALB/C mice (male; 20/20)                       12-16g   By intraperitoneal injection of Eagle' s culture media containing 1 ×10\^^2^ TCID50 CVB3 (0.1 ml) at the age of 4 weeks                  By intragastric administration of 9% AS-IV (600mg/kg; 0.1ml; qd) for 7d after establishing model           By intragastric administration of sodium carboxymethyl cellulose solution (0.1ml; qd) for 7d after establishing model                     1.Mortality rate\                                                1.P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2.Histopathological changes of myocardium\                       2.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         3.TL1A protein                                                   3.P \< 0.01

  [@B35]          Kunming mice (male; 15/15)                      18-22g   By intraperitoneal injection of CVB3 (0.1ml; qod) for 4 times                                                                            By intragastric administration of AS-IV (4.36g/kg; qd) for 15d after establishing model                    By intragastric administration of isometric 0.5% sodium carboxymethyl cellulose solution (20ml/kg; qd) for 15d after establishing model   1.TIMP-1\                                                        1.P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2.MMP-1                                                          2.P \< 0.01
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A20, TNF-α induced protein 3; AS-IV, astragaloside IV; Bax, Bcl2-associated X; Bcl-2, B-cell lymphoma-2; CAT, catalase; cTnI, cardiac troponin I; CD3, clusters of differentiation 3; CD11b, clusters of differentiation 11b; CVB3, coxsackievirus B3; CVF, collagen volume fraction; EF, ejection fraction; EMEM, Eagle's minimal essential medium; FS, shortening fraction; GSH-PX, glutathion peroxidase; HR, heart rate; HW/BW, heart weight/body weight; IGF-1, insulin-like growth factor-1; IGF-1R, insulin-like growth factor-1R; IGFBP3, Insulin-like growth factor binding protein 3; IL-1β, interleukin-1β; IL-6, interleukin-6; IL-17, interleukin-17; IL-23, interleukin-23; LVEDd, left ventricular end-diastolic dimensions; LVEDs, left ventricular endsystolic dimensions; LVEF, left ventricular ejection fraction; MCP-1, monocyte chemoattractant protein-1; MIF, macrophage migration inhibitory factor; MMP-1, matrix metalloproteinase-1; MPO, myeloperoxidase; NF-κB, nuclear factor-κB; P38MAPK, P38 mitogen-activated protein kinase; PICP, carboxyterminal propeptide of type I procollagen; PINP, aminoterminal propeptide of type I procollagen; PIP, propeptide of procollagen type I; PIIINP, procollagen type III aminoterminal peptide; pSmad2/3, phosphorylated small mothers against decapentaplegic 2/3; PWd, posterior wall thickness in end diastole; RPIM-1640, Roswell Park Memorials Institute 1640; ROS, reative oxygen species; Smad4, drosophila mothers against decapentaplegic 4; Smad7, drosophila mothers against decapentaplegic7; SWd, septal wall thickness; TCID50, tissue culture infectious dose 50; TGF-β1, transforming growth factor-β1; Th17, helper T cell 17; TIMP-1, tissue inhibitor of metalloproteinase-1; TL1A, TNF-like ligand 1 aberrance; TNF-α, tumor necrosis factor-α; T-SOD, total superoxide dimutase.

Study Quality {#s3_3}
-------------

The quality of all the included studies was evaluated and scored from 2 to 5. Two studies employed methods of random allocation ([@B38]; [@B18]). Four studies specified the time of model induction before random allocation ([@B37]; [@B33]; [@B4]; [@B8]). Allocation to different groups was not concealed in any of the studies. Two studies declared compliance with animal welfare regulations ([@B38]; [@B8]). However, no studies reported blinding of caregivers and the methods of random outcome assessment. One study described blinding of outcome assessor ([@B34]). All studies specified complete outcome data and no other sources of bias. Nine studies described the free of selective outcome reporting ([@B37]; [@B36]; [@B38]; [@B17]; [@B4]; [@B18]; [@B8]; [@B31]; [@B35]). The methodological quality is summarized in [**Table 2**](#T2){ref-type="table"}.

###### 

Quality assessment of included studies.

  Study    A        B        C        D        E        F        G        H       I       J       Total
  -------- -------- -------- -------- -------- -------- -------- -------- ------- ------- ------- -------
  [@B37]   ?        **+**    **--**   **--**   **--**   **--**   **--**   **+**   **+**   **+**   4
  [@B36]   **--**   **--**   **--**   **--**   **--**   **--**   **--**   **+**   **+**   **+**   3
  [@B38]   **+**    **--**   **--**   **+**    **--**   **--**   **--**   **+**   **+**   **+**   5
  [@B33]   ?        **+**    **--**   **--**   **--**   **--**   **--**   **+**   ?       **+**   3
  [@B19]   ?        **--**   **--**   **--**   **--**   **--**   **--**   **+**   ?       **+**   2
  [@B17]   ?        **--**   **--**   **--**   **--**   **--**   **--**   **+**   **+**   **+**   3
  [@B20]   ?        **--**   **--**   **--**   **--**   **--**   **--**   **+**   ?       **+**   2
  [@B4]    ?        **+**    **--**   **--**   **--**   **--**   **--**   **+**   **+**   **+**   4
  [@B10]   ?        **--**   **--**   **--**   **--**   **--**   **--**   **+**   ?       **+**   2
  [@B34]   ?        **--**   **--**   **--**   **--**   ?        **+**    **+**   ?       **+**   3
  [@B39]   ?        **--**   **--**   **--**   **--**   **--**   **--**   **+**   ?       **+**   2
  [@B18]   **+**    **--**   **--**   **--**   **--**   **--**   **--**   **+**   **+**   **+**   4
  [@B8]    **--**   **+**    **--**   **+**    **--**   **--**   **--**   **+**   **+**   **+**   5
  [@B31]   ?        **--**   **--**   **--**   **--**   **--**   **--**   **+**   **+**   **+**   3
  [@B35]   ?        **--**   **--**   **--**   **--**   **--**   **--**   **+**   **+**   **+**   3

sequence generation; B: baseline characteristics; C: allocation concealment; D: random housing and animal welfare; E: blinding of caregivers and/or investigators; F: random outcome assessment; G: blinding of outcome assessor; H: complete outcome data; I: selective outcome reporting; J: other sources of bias. "+" indicates low risk of bias; "***-***" indicates high risk of bias; and "?" indicates an unclear risk of bias.

Effectiveness {#s3_4}
-------------

### Mortality {#s3_4_1}

Meta-analysis of 12 studies ([@B37]; [@B36]; [@B38]; [@B33]; [@B19]; [@B17]; [@B4]; [@B10]; [@B34]; [@B18]; [@B8]; [@B31]) showed that AS-IV induces a significant reduction in mortality of VM animals, compared with control \[n = 437, RR 0.34, 95% CI (0.24 to 0.48), P \< 0.0001; heterogeneity: χ^2^ = 8.86, I^2^ = 0%\] ([**Figure 2**](#f2){ref-type="fig"}).

![The forest plot: effects of AS-IV for decreasing mortality compared with control group.](fphar-10-01388-g002){#f2}

### Histopathological Changes of Myocardium {#s3_4_2}

Meta-analysis of eight studies ([@B36]; [@B33]; [@B19]; [@B17]; [@B39]; [@B18]; [@B8]; [@B31]) revealed significant effects of AS-IV on reducing inflammation of the myocardium and pathological score in VM animals, compared with control \[n = 176, MD -1.83 95% CI (-1.95 to -1.71), P \< 0.0001; heterogeneity: χ^2^ = 107.56, I^2^ = 93%\]. After sensitivity analyses, we removed one study ([@B8]) that modeling in mice at the age of 6 weeks. Meta-analysis of seven studies showed significant effects of AS-IV on reducing myocardial inflammation and pathological scores in VM animals \[n = 160, MD -1.13 95% CI (-1.32 to -0.95), P \< 0.0001; heterogeneity: χ^2^ = 2.78, I^2^ = 0%\] ([**Figure 3**](#f3){ref-type="fig"}).

![The forest plot: effects of AS-IV for decreasing the inflammation of myocardium and pathological score compared with control group.](fphar-10-01388-g003){#f3}

### LVEF {#s3_4_3}

Data from meta-analysis of two studies ([@B4]; [@B8]) showed that AS-IV treatment induced significant improvement of LVEF in animals with VM \[n = 40 SMD 4.29 95% CI (3.06 to 5.51), P \< 0.0001; heterogeneity: χ^2^ = 0.66, I^2^ = 0%\] ([**Figure 4**](#f4){ref-type="fig"}).

![The forest plot: effects of AS-IV for improving LVEF compared with control group.](fphar-10-01388-g004){#f4}

### LVEDs {#s3_4_4}

Data from meta-analysis of two studies ([@B4]; [@B8]) revealed significant suppressive effects of AS-IV on LVEDs of VM animals \[n = 40 SMD -2.88 95% CI (-3.83 to -1.94), P \< 0.0001; heterogeneity: χ^2^ = 0.83, I^2^ = 0%\] ([**Figure 5**](#f5){ref-type="fig"}).

![The forest plot: effects of AS-IV for decreasing LVEDds compared with control group.](fphar-10-01388-g005){#f5}

### Cardiac Enzymes and/or Troponin {#s3_4_5}

One study ([@B8]) reported significant reduction CK-MB and CTnI levels of animals with VM treated with AS-IV (P \< 0.05).

### Cardioprotective Mechanisms {#s3_4_6}

Two studies ([@B33]; [@B19]) reported a significant increase in T-SOD of VM animals by AS-IV, compared with the control group \[n = 36 MD 24.81 95% CI (19.88 to 29.73), P \< 0.0001; heterogeneity: χ^2^ = 0.26, I^2^ = 0%\] ([**Figure 6**](#f6){ref-type="fig"}). Two studies ([@B37]; [@B20]) focused on AS-IV-induced reduction of apoptosis index \[n = 44 SMD -3.09 95% CI (-4.03 to -2.15), P \< 0.0001; heterogeneity: χ^2^ = 1.76, I^2^ = 43%\] ([**Figure 7**](#f7){ref-type="fig"}), two ([@B33]; [@B19]) on AS-IV-induced increase in GSH \[n = 36 SMD 3.07 95% CI (1.98 to 4.16), P \< 0.0001; heterogeneity: χ^2^ = 1.94, I^2^ = 49%\] ([**Figure 8**](#f8){ref-type="fig"}), two ([@B39]; [@B8]) on AS-IV-mediated reduction of TNF-α (P \< 0.05), one ([@B33]) on reduction of ROS levels by AS-IV, one ([@B20]) on AS-IV-mediated increase in Bcl-2 (P \< 0.05) and reduction of Bax (P \< 0.05), one ([@B8]) on AS-IV-triggered NF-κB (P \< 0.05), and one ([@B8]) on reduction of IL-6 by AS-IV (P \< 0.05). A schematic representation of the cardioprotective mechanisms of AS-IV is summarized in [**Figure 9**](#f9){ref-type="fig"}.

![The forest plot: effects of AS-IV for increasing the T-SOD compared with control group.](fphar-10-01388-g006){#f6}

![The forest plot: effects of AS-IV for reducing apoptosis index compared with control group.](fphar-10-01388-g007){#f7}

![The forest plot: effects of AS-IV for increasing GSH compared with control group.](fphar-10-01388-g008){#f8}

![A schematic representation of cardioprotective mechanisms of astragaloside IV for viral myocarditis. Solid lines indicate established effects, whereas dashed lines represent putative mechanisms.](fphar-10-01388-g009){#f9}

Discussion {#s4}
==========

Summary of Evidence {#s4_1}
-------------------

To our knowledge, this is the first preclinical systematic review (including 15 *in vivo* studies on a total of 577 animals) focused on evaluating the efficacy of AS-IV against VM and its potential mechanisms of action. Our findings clearly support cardioprotective effects of AS-IV in animal models of VM, mainly through improving anti-remodeling of the myocardium, anti-inflammatory, anti-apoptosis, anti-virus, antioxidant, and alleviation of myocardial fibrosis.

Methodological Considerations {#s4_2}
-----------------------------

Assessing of the validity of the included studies is a key component of a systematic review, and subsequently affects its analysis, interpretation and conclusions. Based on the Cochrane Handbook for Systematic Reviews of Interventions ([@B11]), the validity of an individual study should include two dimensions: external validity and internal validity. The former refers to whether the study is asking the appropriate research questions and the latter is in a manner free from the risk of bias of the included studies. In the present study, an appropriate research question was initially set up to evaluate the efficacy and possible mechanism of AS-IV in the treatment of the animals with VM using preclinical systematic review method. When assessments of methodological quality of included preclinical studies, two main risk of bias tools have been developed, including the Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies (CAMARADES) 10-item checklist ([@B32]) and the SYstematic Review Centre for Laboratory animal Experimentation (SYRCLE)'s Risk of Bias tool ([@B12]). The CAMARADES 10-item checklist is specific for stroke and neuroprotective study on animal model while the SYRCLE's Risk of Bias tool is extensively used to assess the methodological quality of animal studies. Here, we selected the SYRCLE's Risk of Bias tool to assess the quality of included study and the result indicated that the quality scores of all studies were generally moderate. Thus, we should treat the present results cautiously when applying the study's findings.

Accumulating evidence demonstrates that animal reports on biomedical research are often inadequate in many areas ([@B15]). An earlier survey evaluated 271 randomly selected articles about animal reports by the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs). The results showed that 59% articles overall declared the hypotheses or objectives of the study and the characteristics and number of animals used. Randomization (87%) or blindness (86%) was not used in the majority of the articles to reduce bias of animal selection and outcome assessments. In total, 70% of the articles used statistical methods to fully describe publications and present the results in an accurate manner ([@B14]). Similarly, the articles selected for our analysis had methodological deficiencies, such as seldom using the blind method and allocation concealment. Therefore, concerns of poor experimental design and lack of transparent reports are raised, which can lead to failure of translation of preclinical animal research into clinical treatments for human diseases ([@B2]). Reporting guidelines develop clear and standard checklist formats to make animal reports more complete and transparent, and thus increase the value of animal reports in clinical practice ([@B24]). The Animal Research: Reporting In Vivo Experiments (ARRIVE) guidelines, which provide a checklist of 20 items to promote high-quality, comprehensive reporting, have been accepted by over 300 research journals worldwide ([@B15]). We recommend adherence to these guidelines for the further design of animal studies. In particular, attention should be paid to calculation of sample size, blinding of outcome assessor and blinding of caregivers ([@B21]). As a minimum requirement, harmonized animal research reporting principles (HARRP) has been set up based on a comparative analysis of the ARRIVE guidelines by the Gold Standard Publication Checklist (GSPC) and the Institute of Laboratory Animal Research (ILAR) Guidance. Thus, the HARRP provided the minimal reporting standards for animal-based research ([@B25]).

Implications {#s4_3}
------------

This study confirmed that AS-IV induces a significant reduction in mortality, improves myocardial pathology, and suppresses expression of cardiac enzymes, supporting its utility as a therapeutic option for patients with VM. However, translation of preclinical experiments remains challenging in predicting the effectiveness of therapeutic strategies in clinical trials ([@B9]). The differences in drug doses and time of drug administration between humans and animals are considered the main reasons underlying failure of translation of research from bench to patient bedside ([@B2]). It is important to note that the 15 articles included in this study are not consistent in terms of drug dose and time of drug administration. Thus, we recommend establishing drug concentration gradients and grouping administration times to establish the optimal treatment strategy. In view of the differences between clinical trials and animal research, further high-quality randomized controlled trials of AS-IV for VM are required.

Several methods are commonly used for establishing animal models of myocarditis. (1) CVB3 or encephalomyocarditis virus (EMCV) injection: the advantages of this model is use of virus, which is close to clinical practice and suitable for studying CVB3 replication. However, this method is associated with high mortality rates and requires high biosafety standards. (2) Reovirus or murine adenovirus type 1 (MAV-1) injection is a unique model of pediatric myocarditis but is not clinically relevant. (3) *Trypanosoma cruzi* (*T. cruzi*) infection model, which could recapitulate the course of Chagas disease, but requires a long period for study. (4) Immunization with α-myosin heavy chain (α-MyHC) or troponin I peptide and complete Freund's adjuvant (CFA). The limitation of this model, which is suitable for studying transition from myocarditis to DCM, is non-physiological disease induction. (5) T cell receptor specific to α-MyHC (TCR-M) transgenic mice. The advantages of this model are biosafety and suitability for studying the pathophysiology of heart-specific T cells. However, the lack of non-specific T cells presents a drawback. (6) Programmed cell death protein-1 (PD-1)/PD-1 ligand (PD-L1) deficiency. This model is suitable for investigating the side-effects of anti-PD-1/PD-1L therapy but involves multiple organs. (7) A human leukocyte antigen (HLA-DQ8) transgenic mouse model is beneficial for studying cardiac antigen presentation but a human-mouse chimeric system is lacking at present ([@B1]). All the studies included in this review utilized a myocardial model induced by CVB3 injection. Since CVB3 is closely related to the pathogenesis of myocarditis in human, this method of modeling is rational. We therefore recommend application of CVB3 to establish models of VM.

Mechanisms {#s4_4}
----------

Based on the findings of the included studies, the possible mechanisms of AS-IV mediated cardiovascular protection are as follows: (1) antioxidant through increasing T-SOD, GSH-PX and CAT levels ([@B33]; [@B19]) to inhibit release of ROS and MPO ([@B33]), (2) anti-inflammatory activity through suppression the TLR4/P38MAPK/MCP-1 ([@B33]; [@B39]) and IL23/IL17 pathways ([@B18]) and inhibition of NF-κB ([@B39]) as well as MIF ([@B17]) and A20 (Liu et al., 2015), (3) alleviation of myocardial fibrosis through inhibiting TGF-β1, Smad2/3 and Smad4 and enhancing Smad7 ([@B4]) and increasing TIMP-1to reduce MMP-1 release ([@B35]), (4) prevention of viral spread through increasing IFN-γ ([@B38]) and decreasing CAR expression ([@B36]), (5) inhibition of apoptosis through enhancing the Bcl-2/Bax ratio ([@B20]), (6) anti-remodeling of myocardium through suppressing the expression of IGF-1, IGF-1R and IGFBP3 ([@B10]).

Conclusion {#s5}
==========

The collective research clearly demonstrates that AS-IV decreases mortality, inflammation of the myocardium, pathological score and cardiac enzyme activity and improves heart function. Moreover, AS-IV exerts potential cardioprotective function of in VM primarily *via* improving anti-remodeling of myocardium, anti-inflammatory, anti-apoptosis, anti-virus, antioxidant and alleviation of myocardial fibrosis. Thus, AS-IV is a cardioprotective recruit for further clinical trials on VM.
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